NCT05419180CompletedPhase 4
Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Source: ClinicalTrials.gov · Last updated 24 Jul 2024
Brief summary (registry, in English)
This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 16 May 2022
- Start date
- 13 Oct 2022
- Primary completion date
- 13 Jun 2024
- Lead sponsor
- Biocodex
- NCT number
- NCT05419180
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 52
- From 13 Oct 2022 to the primary completion date, 13 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participating simultaneously in another interventional clinical trial or in a period of exclusion following a previous trial,
Other
- \- Retrospective part of the research : Patients objecting to the collection of their data will not participate in the research.
- \- Prospective part of the research :
- Patients with the following criteria will not be able to participate in the prospective part of the research:
- Whose state of health does not allow him to give his consent,
- Under guardianship or curatorship,
- Under judicial protection or person deprived of liberty.
Who the study is looking for
- Retrospective part of the research:
- The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:
- With pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy,
- Receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days,
- Having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment),
- For which an information note indicating the possibility of opposing the processing of data has been provided.
- Prospective part of the research:
- Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:
- Currently treated with stiripentol in combination with carbamazepine for at least 15 days and still being followed in the center,
- Weighing at least 5 kg (minimum weight in accordance with the blood volume taken),
- Having read, or whose parents have read, the information note and signed the consent form. For children, if their level of understanding allows it, their consent will also be sought,
- Having sufficient knowledge, or whose parents or legal guardians have sufficient knowledge, of the French language to read, understand and complete the research documents,
- Members or beneficiaries of a social security scheme. These patients, both children and adults, will be welcomed at the CIC.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.